RANI
Rani Therapeutics Holdings, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.70
P/S
33.20
EV/EBITDA
-1.07
DCF Value
$0.35
FCF Yield
-34.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
75.0%
Operating Margin
-2345.9%
Net Margin
-1817.1%
ROE
-718.5%
ROA
-50.6%
ROIC
-80.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.5M | $-10.3M | $-0.07 |
| FY 2025 | $1.6M | $-29.7M | $-0.45 |
| Q3 2025 | $0.00 | $-5.4M | $-0.12 |
| Q2 2025 | $0.00 | $-6.7M | $-0.18 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.66
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.